CrossBridge Bio

Lilly's $300M CrossBridge Bet Isn't About ADCs — It's About Buying the Next Decade of Oncology Pricing Power

Article: Opinion

Lilly’s $300M CrossBridge Bet Isn’t About ADCs — It’s About Buying the Next Decade of Oncology Pricing Power

Eli Lilly's $300M acquisition of CrossBridge Bio targets dual-payload ADCs — a manufacturing cost doubler that signals a bold...

By Moe Alsumidaie
May 15, 2026

Read More